about
Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic FibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisCombination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOscillating devices for airway clearance in people with cystic fibrosisAntibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosisAntibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosisNebuliser systems for drug delivery in cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisAntibiotic adjuvant therapy for pulmonary infection in cystic fibrosisInhaled antibiotics for pulmonary exacerbations in cystic fibrosisAntibiotic adjuvant therapy for pulmonary infection in cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisInhaled antibiotics for long-term therapy in cystic fibrosisAntibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosisOscillating devices for airway clearance in people with cystic fibrosisCombination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisNebuliser devices for drug delivery in cystic fibrosisAntimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisNebulised anti-pseudomonal antibiotics for cystic fibrosisAntibiotic treatment forStenotrophomonas maltophiliain people with cystic fibrosisThe Evolution of Cystic Fibrosis CareFluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosisThe YfiBNR signal transduction mechanism reveals novel targets for the evolution of persistent Pseudomonas aeruginosa in cystic fibrosis airwaysBiomarkers in Exhaled Breath Condensate Are Not Predictive for Pulmonary Exacerbations in Children with Cystic Fibrosis: Results of a One-Year Observational StudyBackground and EpidemiologyComparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patientsDetermination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary functionPseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentDesign and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptomsDenufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis.Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.
P2860
Q22306312-18CA43C1-E3E8-4433-8ACC-53BEDFA9E726Q24186413-E94F66BD-A468-4CC3-BF7B-A7A0E54F1002Q24188024-CACB21AE-7994-4D98-BECF-A7DBA2F869CBQ24188054-8F4A6323-5C14-42A3-A621-816ACBDB2670Q24194837-FA174E0D-2502-43B3-B5A9-1DAF750E7378Q24197517-69B5298B-8ABC-404A-BB51-BB079BE2EDC7Q24197766-7029E751-08FB-4BCF-B481-AC8A50B60F17Q24197879-D3D14A13-EB7B-44F6-8398-54F4F58DF76CQ24201620-0B29829D-FCA0-4CF7-BDDD-E76E3255BEA6Q24202222-B2DBDF5C-A08B-4BFA-88E2-C42AE620D9EAQ24202283-034D4716-235D-4279-B9EA-F60E68BFF7DEQ24234613-96DA0457-2811-4762-AED9-3031212E7C48Q24234964-AD01ABF2-4B17-4412-91C9-148CD7D6361AQ24235635-1AED9FA8-AD72-4C4A-A7B7-79DF352E1CF7Q24235754-175AA8D7-2F46-46F8-BC17-CF8E53B144B3Q24241016-C37B8ACA-4225-4858-A3F9-03E23FDC25D0Q24242073-EC1ADF04-99C7-4E45-8300-E3A42754DB94Q24242712-5BE9B891-A19F-42FC-A39E-9002EF20D9F0Q24243047-C504B628-113B-4DB0-9047-981189DDA8B6Q24247996-80A60843-EE2C-490D-8B66-920DDD8311D9Q26471114-12F260E8-70F4-488B-80BC-8BC254CBAF42Q26999299-FD56D60A-3E69-4676-A0B8-494FB0B9F809Q27004711-275B4126-3B6A-4C2A-8697-3DEE43A31239Q28480433-E9CB5CD5-0EA4-41D4-BF5A-4350EEE3655AQ28551208-851EF71D-AD6F-4FDE-9007-585812AA36D4Q30248742-10197ED3-AAD2-4996-A7F8-E29B7718FE7CQ30413773-4D0CBBD8-8752-4ACC-82FE-F7D3E94D49C8Q30816650-138EB06C-7C4D-4C6A-8DE8-20263EBB7299Q33650377-83286898-C577-4B34-B164-507EBB5E2B7AQ33725822-CBB66383-F4A0-451F-B33D-BED6AE86C86DQ33782278-0EF628D7-F3F8-4753-86EA-02EBE30B4019Q33824149-708C83E9-0A10-4BB6-A5E5-0303021C739BQ33836302-522B7F3E-CFE2-4DB0-9318-AFFEC2EB6490Q33915965-8B12DA00-D36A-42EC-9995-AAD5B0AD903AQ34155594-7DBBE161-4601-42FA-87D5-776197449B16Q34320262-79143FB5-FAC4-4556-9A31-1A0572C5E885Q34324105-10C7B856-81FD-4367-8690-6C821A576AD8Q34390999-6EAD94ED-96E3-4FAB-9F1D-5641649B4632Q34422248-6F63C25D-90BB-4AE5-A86F-4EAC02566DDBQ34554419-F112AEDE-E584-4197-8492-8E97E80F45C5
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Defining a pulmonary exacerbation in cystic fibrosis.
@en
type
label
Defining a pulmonary exacerbation in cystic fibrosis.
@en
prefLabel
Defining a pulmonary exacerbation in cystic fibrosis.
@en
P2093
P356
P1476
Defining a pulmonary exacerbation in cystic fibrosis.
@en
P2093
Montgomery AB
Rosenfeld M
Williams-Warren J
P304
P356
10.1067/MPD.2001.117288
P407
P577
2001-09-01T00:00:00Z